Dr. Heimberger’s laboratory will be responsible for generating somatic genetic brain tumor models for testing the efficacy of the T-αFgl2 cell therapy across different types of brain tumor models. Dr Heimberger has created and maintains a colony of genetically engineered murine (GEM) Ntv-a mice including the PDGFB + Fgl2 (Latha et al, JNCI, 2018) and the PDGFB and STAT3 (Doucette, Neuro Oncol, 2012) high-grade glioma models. For Aim 2.1, Dr. Heimberger’s laboratory will induce the gliomas at Northwestern University and then ship to MD Anderson Cancer Center to Dr. Li’s laboratory to randomize into treatment to either a control cohort or the T-αFGl2 cell therapy. During the first year of the grant, given Dr. Heimberger’s relocation from MD Anderson Cancer Center to Northwestern, activities will include establishing the breeding and lentivirus infrastructure needed for the generation of the mice. During years 2-3, T-αFGl2 therapy will be assessed in the PDGFB + Fgl2 model and then validated in years 4-5 in the PDGFB and STAT3 model. Correlative immunohistochemistry and multiplex immunofluorescence can be conducted by Dr. Heimberger’s Laboratory. Sincerely,
|Effective start/end date||8/1/21 → 6/30/26|
- University of Texas M. D. Anderson Cancer Center (3001813107//1R01NS122857-01)
- National Institute of Neurological Disorders and Stroke (3001813107//1R01NS122857-01)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.